MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary and Recent Business Highlights:Total revenue increased 23% year-over-year to $75.3 million Gross margin of 76.5% versus 74% in Q1 2025 Net loss of $1.8 million versus $3.0 million in Q1 2025 Adjusted EBITDA of $3.7 million versus an Adjusted EBITDA loss of $0.3 million in Q1 2025 Expanded AI-enabled order management platform with the implementation of new operational capabilities to execute the Medicare prior authorization requirement for PCDs Repurchased $1.1 million of stock under the Company’s share repurchase program Received...

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.Title:Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 12, 2026Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 60968 Participants may dial in using the numbers above and ask to be...

Quarterly revenue of $81.7 million, representing an increase of 15% year-over-year Quarterly gross margin of 79.2% and an increase in gross profit of 15% year-over-year Record Active Buyers of 1.71 million, representing an increase of 25% year-over-year Ended the quarter with cash and cash equivalents, restricted cash, and marketable securities of $54.4 million, up 1.3 million from the previous quarter Issued a revised full year 2026 financial outlook, raising expectations for Revenue, Gross Margin and Adjusted EBITDA marginOAKLAND, Calif., May 04, 2026 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, announced today its financial results for the first quarter ended March 31, 2026 and updated full year 2026 financial outlook. “We are proud...

First quarter revenue growth of 1.6% First quarter diluted EPS of $(0.39); adjusted diluted EPS of $0.10 First quarter operating cash flow of $12.8 millionMINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2026. “Our first quarter results reflect revenue growth and improved adjusted operating income and cash flow,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems. “We remain focused on the factors within our control, including prioritizing revenue-generating activities and maintaining disciplined cost management, while continuing...

All financial figures are in Canadian dollars unless otherwise noted CALGARY, Alberta, May 04, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson” or the “Company”) announced today its financial and operating results for the three months ended March 31, 2026.Key Highlights:Expanded core infrastructure footprint with the $400 million Chauvin acquisition, strengthening the long-term growth platform, and sanctioned the Hardisty Connection growth project, which will enhance and extend connectivity at the terminal Successfully completed a $215 million equity financing, which partially funded the Chauvin acquisition, reflecting our commitment to capital discipline Delivered quarterly Infrastructure EBITDA(1) of $156 million, consistent with the prior year Completed organizational restructuring...

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 04, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2026. “Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business,” said Scott Hutton, Chief Executive Officer. “Test volumes grew 29%, Development Services revenue doubled, and average revenue per test increased through expanded payer coverage and improved revenue cycle management,...

Highlights (All comparisons are to the prior year period unless otherwise noted):Net sales of $528.8 million for the quarter, up 4.2% Diluted earnings per share (“EPS”) of $1.43, down 24% Adjusted diluted EPS* of $1.57, down 22% Generated $43.8 million of cash from operating activities; repurchased $51 million of its sharesCOLMAR, Pa., May 04, 2026 (GLOBE NEWSWIRE) — Dorman Products, Inc. (the “Company” or “Dorman”) (NASDAQ: DORM), a leading supplier in the motor vehicle aftermarket industry, today announced its financial results for the first quarter ended March 28, 2026. Kevin Olsen, Dorman’s Chairman, President, and Chief Executive Officer, stated, “We started the year with solid financial performance that was in line with our expectations. Despite ongoing uncertainty in the broader economy and geopolitical environment, we...